Alnylam Pharmaceuticals announced that it has entered into privately negotiated agreements to partially repurchase approximately $34.4 million principal amount of its 1.00% Convertible Senior Notes due 2027 for a total cash cost of about $51.9 million, including accrued interest. Following the transaction, roughly $362.8 million of the notes are expected to remain outstanding.

Source: Alnylam Pharmaceuticals, Business Wire